GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kopran Ltd (BOM:524280) » Definitions » COGS-to-Revenue

Kopran (BOM:524280) COGS-to-Revenue : 0.62 (As of Jun. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Kopran COGS-to-Revenue?

Kopran's Cost of Goods Sold for the three months ended in Jun. 2024 was ₹859 Mil. Its Revenue for the three months ended in Jun. 2024 was ₹1,394 Mil.

Kopran's COGS to Revenue for the three months ended in Jun. 2024 was 0.62.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Kopran's Gross Margin % for the three months ended in Jun. 2024 was 38.39%.


Kopran COGS-to-Revenue Historical Data

The historical data trend for Kopran's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kopran COGS-to-Revenue Chart

Kopran Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.63 0.65 0.60 0.68 0.68

Kopran Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.62 0.63 0.78 0.62

Kopran COGS-to-Revenue Calculation

Kopran's COGS to Revenue for the fiscal year that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=4162.138 / 6100.888
=0.68

Kopran's COGS to Revenue for the quarter that ended in Jun. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=859.002 / 1394.365
=0.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kopran  (BOM:524280) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Kopran's Gross Margin % for the three months ended in Jun. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 859.002 / 1394.365
=38.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Kopran COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Kopran's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Kopran Business Description

Traded in Other Exchanges
Address
Dr. E. Moses Road, 1076, Parijat House, Worli, Mumbai, MH, IND, 400 018
Kopran Ltd is an Indian based pharmaceutical company. It is engaged in manufacturing of Formulation (Finished Dosage Form) and Active Pharmaceutical Ingredients (API) i.e., Pharmaceuticals. It manufactures dosage forms including, tablets, capsules, dry powder, suspension, and injectables. Some of its product range includes antibiotics, cardiovascular, anti-diabetes, respiratory, pain management, and gastrointestinal. Geographically, it has a presence in India; South Africa; Ethiopia; Zambia; Egypt; Jordan and Rest of World.

Kopran Headlines

No Headlines